Researchers from King’s College London and South London and Maudsley NHS Foundation Trust have published the first publicly funded, placebo-controlled NHS trial of psilocybin-assisted therapy for treatment-resistant depression. The results, published in Nature Medicine, are among the strongest yet.
For people who had already failed multiple conventional treatments, a single 25 mg dose of psilocybin combined with psychological support produced remission in 40% of participants within three weeks.
Why this study matters
Treatment-resistant depression (TRD) affects around one-third of people with major depressive disorder. By definition, these are patients who have already failed at least two previous treatments and often live with depression for years or even decades. The average participant in this trial had experienced significant depression for around 20 years before entering the study.
Unlike many previous psychedelic studies, this wasn’t conducted in a private clinic or heavily controlled research environment alone. It was designed to answer a practical question: Can psilocybin therapy actually work inside the NHS?
The trial
The study recruited 60 adults with treatment-resistant depression. Participants were randomly assigned to receive either:
- one 25 mg dose of pharmaceutical psilocybin
- or a placebo
Both groups received identical preparation sessions, psychological support during dosing, and integration afterwards.
The differences between groups after just three weeks were profound:
- 43% of people receiving psilocybin showed a clinical treatment response.
- 40% entered remission.
- In the placebo group, only 3% achieved either outcome.
These improvements remained six weeks later, with response rates rising to 50% in the psilocybin group while remission remained at 40%.
The researchers also observed improvements in:
- anxiety
- wellbeing
- overall health
- work and social functioning
Many of the effect sizes were exceptionally large for psychiatric research.
The experience behind the numbers
Clinical scores tell only part of the story. Speaking to the Independent, one participant described their session as emotionally overwhelming, yet ultimately transformative.
“It got very intense two or three times.”
During the experience they recalled a vivid image of their father holding their sister, both of whom had died.
“I felt like it was a way of them saying we are here.”
Afterwards they said:
“It helped me understand my depression more and just feel my feelings.”
And perhaps most importantly:
“It was very difficult—very painful—but I think that was what I needed.”
That captures something these studies repeatedly find. Many participants report confronting grief, fear, trauma or deeply buried emotions that had previously been avoided. Improvement appears to come from escaping finally experiencing these difficult feelings.
It wasn’t all straightforward
As impressive as the results are, the researchers are careful not to overstate them. One major challenge is that nearly everyone who received psilocybin correctly guessed they had received psilocybin. That means expectancy effects almost certainly contributed to some of the observed improvements.
The authors openly discuss this limitation, noting that the psychological effects, expectations and pharmacology probably work together and may actually be inseparable parts of the treatment. In other words, unlike a conventional antidepressant, the subjective experience may be part of how the therapy works.
Safety remains one of the biggest questions surrounding psychedelic therapy.
In this study:
- most adverse events were mild
- serious adverse events were rare
- nearly two-thirds of recorded adverse events were judged unrelated to the study drug
- no adverse events of special interest were recorded
The researchers concluded the treatment was generally well tolerated within this clinical setting.
Halfway through the study, researchers moved treatment out of a hospital research facility and into a community mental health building and nothing dramatic happened. No new safety concerns emerged.
In fact, the researchers suggest this type of calm community environment may actually be preferable to hospital wards, which can increase anxiety unnecessarily. That’s an important point, because if psilocybin eventually becomes licensed, it may not require expensive hospital infrastructure.It may be possible to conduct in a more comfortable room with trained therapists..
The bigger picture
This study doesn’t say psilocybin is a cure for depression. The trial was relatively small, followed participants for only six weeks, and larger studies are still needed for us to learn more about its limitations.
But it does tell us that psilocybin-assisted therapy be delivered safely within a public healthcare system while producing clinically meaningful improvements in people who have exhausted conventional options. As Professor James Rucker put it:
“The wider evidence base for psilocybin therapy is growing rapidly, and looks increasingly promising.”
For decades, treatment-resistant depression has left millions cycling through medications that often provide only modest relief and come with negative side effects.
This study suggests that psilocybin administered under the right conditions may allow some people to process difficult emotions and begin a process of healing.
For 40% of the participants in this NHS trial, one carefully supported psychedelic experience was enough for depression to no longer meet the criteria for a clinical diagnosis. That’s unheard of in psychiatry and highlights the huge potential these compounds offer humanity.
Source: Rucker, J.J., Mantingh, T., Kerr-Gaffney, J. et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nat Med (2026). https://doi.org/10.1038/s41591-026-04541-0
Keep up with the research here.
